Inventor

Valentino J. Stella

Inventor

Lawrence, KS, US

Overview

1979–2021

Patent span

Chemistry

Primary field (CPC C)

Patents· 46 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary

A61KPreparations for medical, dental or toiletry purposes22%

C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium21%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations20%

C07DHeterocyclic compounds14%

C07KPeptides4%

C07HSugars3%

B82YSpecific uses or applications of nanostructures2%

C07BGeneral methods of organic chemistry2%

C07CAcyclic or carbocyclic compounds2%

Y02PClimate change mitigation technologies in the production or processing of goods2%

PatentTitleYear

11,091,507Methods of treating Parkinson's disease2021 10,717,721Substituted piperaziniums for the treatment of emesis2020 10,662,146Prodrugs of fencamfamine2020 10,577,381Prodrugs of 2,4-pyrimidinediamine compounds and their uses2020 10,487,098Soluble C5aR antagonists2019 10,329,314Soluble C5aR antagonists2019 10,208,073Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator2019 10,174,061Carbidopa and L-dopa prodrugs and methods of use2019 9,908,907'Substituted piperaziniums for the treatment of emesis'2018 9,532,998'Prodrugs of 2,4-pyrimidinediamine compounds and their uses'2017 9,446,059'Carbidopa and L-dopa prodrugs and methods of use'2016 9,403,772'4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator'2016 9,266,912'Prodrugs of 2,4-pyrimidinediamine compounds and their uses'2016 8,895,586'Methods of treating emesis'2014 8,785,437'Prodrugs of 2,4-pyrimidinediamine compounds and their uses'2014 8,476,263'Prodrugs of 2,4-pyrimidinediamine compounds and their uses'2013 8,426,450'Substituted 4-phenyl pyridines having anti-emetic effect'2013 8,211,889'Prodrugs of 2,4-pyrimidinediamine compounds and their uses'2012 8,211,888'Prodrugs of 2,4-pyrimidinediamine compounds and their uses'2012 8,080,544'Prodrugs of CGRP receptor antagonists'2011 7,625,878'Sulfoalkyl ether-alkyl ether cyclodextrin derivatives'2009 7,563,892'Prodrugs of 2,4 pyrimidinediamine compounds and their uses'2009 7,538,108'Prodrugs of 2,4-pyrimidinediamine compounds and their uses'2009 7,449,458'Prodrugs of 2,4-pyrimidinediamine compounds and their uses'2008 7,244,718'Water soluble prodrugs of hindered alcohols'2007 6,872,838'Water soluble prodrugs of hindered alcohols'2005 RE038333'Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability'2003 6,451,776'Water soluble prodrugs of hindered alcohols'2002 6,204,257'Water soluble prodrugs of hindered alcohols'2001 6,133,248'Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof'2000 6,069,249'Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability'2000 6,046,177'Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations'2000 6,043,230'Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability'2000 5,985,856'Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof'1999 5,977,089'Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability'1999 5,922,695'Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability'1999 5,874,418'Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use'1999 5,874,029'Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent'1999 5,833,891'Methods for a particle precipitation and coating using near-critical and supercritical antisolvents'1998 5,672,584'Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability'1997 5,376,645'Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof'1994 5,134,127'Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof'1992 4,980,343'Aminooxodihydroisoindoloquinazoline carcinostatic agents'1990 4,960,790'Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof'1990 4,650,803'Prodrugs of rapamycin'1987 4,163,058'Derivatives of 5,5-diphenylhydantoin exhibiting enhanced solubility and the therapeutic use thereof'1979

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1979–2021Based in Lawrence, KS, US· patent location history

1987–2009Patents assigned to UNIV KANSAS (12)· patent assignee history

1999–2003Patents assigned to GILEAD SCIENCES INC (5)· patent assignee history

2008–2020Patents assigned to RIGEL PHARMACEUTICALS INC (10)· patent assignee history

2011–2017Patents assigned to STELLA VALENTINO J (7)· patent assignee history

2013–2020Patents assigned to HELSINN HEALTHCARE SA (5)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
UNIV KANSAS	12	1987–2009
RIGEL PHARMACEUTICALS INC	10	2008–2020
STELLA VALENTINO Jself	7	2011–2017
GILEAD SCIENCES INC	5	1999–2003
HELSINN HEALTHCARE SA	5	2013–2020

Locations

Location	Patents	Span
Lawrence, KS, US	46	1979–2021